BioCentury | Feb 9, 2018
Clinical News

Hisamitsu's HP-3070 meets in Phase III for schizophrenia

Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530) reported data from a double-blind, U.S. Phase III trial in 617 patients with schizophrenia showing that HP-3070 met the primary endpoint of reducing Positive and Negative Syndrome Scale (PANSS) total...
BioCentury | Sep 12, 2016
Clinical News

Asenapine maleate transdermal patch: Phase III started

Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, international Phase III trial to evaluate 2 dose levels of asenapine maleate transdermal patches in about 612 patients. Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product:...
BioCentury | May 5, 2014
Clinical News

HP-3070: Phase I started

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary began a U.S. Phase I trial to evaluate HP-3070 in patients with schizophrenia. Hisamitsu plans to start a U.S. Phase II trial of the product in its fiscal year ending...
Items per page:
1 - 3 of 3